MicroRNA Post-transcriptional Regulation of the NLRP3 Inflammasome in Immunopathologies


Tezcan G., Martynova E. V. , Gilazieva Z. E. , McIntyre A., Rizvanov A. A. , Khaiboullina S. F.

FRONTIERS IN PHARMACOLOGY, vol.10, 2019 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 10
  • Publication Date: 2019
  • Doi Number: 10.3389/fphar.2019.00451
  • Journal Name: FRONTIERS IN PHARMACOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Keywords: NLRP3, inflammasome, microRNA, inflammation, disease, RECEPTOR PROTEIN-3 INFLAMMASOME, TYPE-2 DIABETES-MELLITUS, TOLL-LIKE RECEPTORS, KAPPA-B ACTIVATION, CUTTING EDGE, SIGNALING PATHWAY, INTESTINAL INFLAMMATION, CELL-PROLIFERATION, CERVICAL-CANCER, HOST-DEFENSE
  • Bursa Uludag University Affiliated: No

Abstract

Inflammation has a crucial role in protection against various pathogens. The inflammasome is an intracellular multiprotein signaling complex that is linked to pathogen sensing and initiation of the inflammatory response in physiological and pathological conditions. The most characterized inflammasome is the NLRP3 inflammasome, which is a known sensor of cell stress and is tightly regulated in resting cells. However, altered regulation of the NLRP3 inflammasome is found in several pathological conditions, including autoimmune disease and cancer. NLRP3 expression was shown to be post-transcriptionally regulated and multiple miRNA have been implicated in post-transcriptional regulation of the inflammasome. Therefore, in recent years, miRNA based post-transcriptional control of NLRP3 has become a focus of much research, especially as a potential therapeutic approach. In this review, we provide a summary of the recent investigations on the role of miRNA in the post-transcriptional control of the NLRP3 inflammasome, a key regulator of pro-inflammatory IL-1 beta and IL-18 cytokine production. Current approaches to targeting the inflammasome product were shown to be an effective treatment for diseases linked to NLRP3 overexpression. Although utilizing NLRP3 targeting miRNAs was shown to be a successful therapeutic approach in several animal models, their therapeutic application in patients remains to be determined.